Nov. 4-5, 2020
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: July 31, 2020
- Pre-Proposal Teleconference: Aug. 12, 2020 @ 1:00 p.m. Central
- Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
- UF BPA & UF ADP Class Quotes Due: Sept. 18, 2020
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- RESPIRATORY INTERLEUKINS - NA
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to 27 August 2015, but not currently available the committee may still make a formulary recommendation.
|
- AirDuo Digihaler
- ArmonAir Digihaler
- Bafiertam
- Breztri Aerosphere
- Conjupri
- Cystadrops
- Dojolvi
- Dupixent Pen
- Enspryng
- Evrysdi
- Gavreto
- Gimoti
- Hemady
- Inqovi
- Kesimpta
- Lampit
- Mycapssa
- Ongentys
- Onureg
- Ortikos
- Rukobia
- Semglee
- Sevenfact
- Upneeq
- Xywav
|
|
Aug. 5-6, 2020
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: May 6, 2020
- Pre-Proposal Teleconference: May 13, 2020 @ 1:00 p.m. Central
- Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
- UF BPA & UF ADP Class Quotes Due: June 26, 2020*
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
-
PSORIASIS AGENTS - NA:
- Calcitriol
- Calcitrene
- Calcipotriene Clobetasol
- Calcipotriene Monohydrate
- Dovonex
- Enstilar
- Oxsoralen-Ultra
- Soriatane
- Sorilux
- Taclonex
- Tazorac
- Vectical
- SLEEP DISORDERS - WAKEFULNESS PROMOTING AGENTS
- Nuvigil
- Provigil
- Sunosi
- Wakix
- Xyrem
- WHITE BLOOD CELL STIMULANTS - FILGRASTIMS
- Granix
- Neupogen
- Nivestym
- Zarxio
- WHITE BLOOD CELL STIMULANTS - PEGFILGRASTIMS
- Fulphila
- Neulasta
- Udenyca
- Ziextenzo
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. This reflects the delay of the May 2020 P&T meeting Drug Class reviews to August 2020 as noted in the May meeting website posting. Updated utilization data reflecting the past 3 months has been posted to betasam.
|
- Arazlo
- Bynfezia
- Dayvigo
- Fensolvi
- Fintepla
- Halog
- Isturisa
- Koselugo
- Kynmobi
- Licart
- Lyumjev
- Nexlizet
- Nymalize
- Oriahnn
- Pemazyre
- Phexxi
- Qinlock
- Retevmo
- Tabrecta
- Tukysa
- Twirla
- Zeposia
- Zilxi
|
|
May 6, 2020
Uniform Formulary Request for Quote Information
- Uniform Formulary Request for Quote Information (UPDATED April 16, 2020)
- Pre-Proposal Teleconference: Feb. 12, 2020 @ 1:00 p.m.Central
- Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
- UF BPA & UF ADP Class Quotes Due: June 26, 2020*
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- PSORIASIS AGENTS - NA*
- SLEEP DISORDERS - WAKEFULNESS PROMOTING AGENTS*
- WHITE BLOOD CELL STIMULANTS - FILGRASTIMS*
- WHITE BLOOD CELL STIMULANTS - PEGFILGRASTIMS*
*All May 2020 P&T Drug Class Reviews have been delayed due to the COVID-19 Pandemic. We expect to review all classes at the August 2020 P&T Meeting. Please note the new quote solicitation due date of June 26, 2020. Please contact the RFQ POC with any questions Email RFQ POC for questions.
|
- Ayvakit
- Bonsity
- Caplyta
- Esperoct
- Ibrance Tablets
- Nexletol
- Nurtec ODT
- Palforzia
- Reyvow
- Riomet ER
- Tazverik
- Trijardy XR
- Ubrelvy
- Valtoco
- Xcopri
- Zerviate
|
|
Feb. 5-6, 2020
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: Nov. 1, 2019
- Pre-Proposal Teleconference: Nov. 13, 2019 @ 12:00 p.m. Central
- Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
- UF BPA & UF ADP Quotes Due: Dec. 20, 2019
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- PAIN AGENTS - NSAID:
- Duexis
- Qmiiz ODT
- Sprix
- Tivorbex
- Vimovo
- Vivlodex
- Zipsor
- Zorvolex
- Anaprox DS, generics
- Ansaid, generics
- Arthrotec, generics
- Cambia, generics
- Cataflam, generics
- Celebrex, generics
- Choline magnesium trisalicylate, generics
- Clinoril, generics
- Daypro, generics
- Diflunisal, generics
- Disalcid, generics
- Dyloject, generics
- Feldene, generics
- Fenortho, generics
- Ibu, generics
- Indocin IR, generics
- Indocin ER, generics
- Indocin Rectal, generics
- Indocin Suspension, generics
- Lodine, generics
- Lodine XL, generics
- Meclomen, generics
- Mobic, generics
- Nalfon, generics
- Naprelan CR, generics
- Naproxen IR, generics
- Naproxen DR, generics
- Naproxen Suspension, generics
- Orudis, generics
- Oruvail, generics
- Ponstel, generics
- Profeno, generics
- Relafen, generics
- Tolectin, generics
- Toradol cartridge, generics
- Toradol syringe, generics
- Toradol tablet, generics
- Toradol vial, generics
- Voltaren DR, generics
- Voltaren XR tablet, generics
- PAIN AGENTS - PAIN TOPICAL:
- Diclofono
- Flector, generics
- Lidoderm, generics
- Pennsaid drops, generics
- Pennsaid Pump
- Voltaren, generics
- ZTLido
|
- Aklief
- Amzeeq
- Brukinsa
- Consensi
- Enzoclear
- Fasenra Pen
- Gloperba
- Jatenzo
- Oxbryta
- Ozobax
- Pretomanid
- Proair Digihaler
- Secuado
- Talicia
- Trikafta
- Vumerity
- Ziextenzo
|
|
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: July 22, 2025